Geron Corporation Announces Data On The Effects Of Its Cancer Drug, GRN163L, On Multiple Myeloma At the American Society Of Hematology Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 12, 2005--Geron Corporation (Nasdaq:GERN) announced today positive data from studies of its telomerase inhibitor drug, GRN163L, in animal models of human multiple myeloma and in tissue culture experiments with primary CLL patient cells. GRN163L is currently in a Phase 1-2 clinical trial in patients with chronic lymphocytic leukemia (CLL). The multiple myeloma results, from two independent laboratories, were presented in a talk by Masood Shammas, Ph.D., a member of Dr. Nikhil Munshi's group at the Dana Farber Cancer Institute, and in a poster session by Server Ertem, a member of Dr. Malcolm Moore's group at the Memorial Sloan-Kettering Cancer Center.